Clinical Trial Update: Single Dose of pGM169/GL67A in CF Patients [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating a single dose of pGM169/GL67A in cystic fibrosis patients; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• pGM169/GL67A

Snippet

Sponsor: Imperial College London | Conditions: Cystic Fibrosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-01-18